The “Wegven” brand Slimming syringe is sold in the Achak pharmacy in Mitte. The “Wegven” shotgun has been available in Germany for a year.
Jens Kalaene | Image Allianz | Getty pictures
Novo Nordisk On Tuesday it said that it will offer its weight loss medication from Telemealth providers Hims & Hers HealthRO and LIFEDTHD to expand access to blockbuster treatment, as it is no longer lacking in the United States
The shares of HIMS & HULS closed 23% on Tuesday, while Novo Nordisk's shares closed by 4%.
The Danish pharmaceutical maker is breaking up to catch more patients, since many compounding pharmacies are legally prevented from making cheaper, non -approved versions of Wegovy with rare exceptions. The patients flocked to these composite versions, while Wegovy was in deficiency due to the leaking demand.
“We believed that it was really important to work hard to create a collaboration with telemedicine companies so that access to Wegovy can give compounding closing,” said Dave Moore, Executive Vice President of US operations at Novo Nordisk, to CNBC.
“We are very happy about the interest of giving access to brands on Wegven and catching people when they start from increased medicine,” he said.
More CNBC health insurance
Moore added that the new partnerships have the experience for the patients “seamlessly” because they enable them to access them directly from their telemedicine providers, which makes it “very easy” for them to send the medication directly into their houses.
Patients can access Novo Nordisks new direct-to-consumer online pharmacy, Novocare, directly through the telemedicine providers.
This pharmacy offers Wegovy for 499 US dollars in cash per month – about half of the usual monthly list price – for patients without insurance protection for weekly injection.
The price of every telemedicine company may be higher because they probably contain additional services, a spokesman for Novo Nordisk told CNBC.
Stock Diagram -iconstock -Igram -Symbol
Novo Nordisk one -year share card
HIMS & HERS said that it would offer all dose sizes of Wegovy as well as access to 24/7 supply, nutrition instructions and ongoing clinical support this week from $ 599 per month for justified cash playing patients with a reception.
The medication costs HIMS & HEATS more, as it goes with additional access to care, said the company's CEO, Andrew Dudum, in an interview with CNBC. He said that the company's partnership with Novo Nordisk will serve as a case study, how patients receive access to “great medicine” and other forms of treatment and receive and receive prices for “great medicine”.
Ro decided on the lower price and announced on Tuesday that it offers access to all doses of Wegovy for $ 499 per month. The company offers messaging around the clock, individual coaching, educational content and more through its monthly membership called The Body Program, which does not contain the medication costs.
“Adding Novo Nordisks from the FDA to the best available cash price helps more patients in the whole country to receive obesity that they need to achieve their goals, especially in patients without insurance,” said R-CEO Zach Reitano in a release.
At the beginning of this month, Hims & Hert announced that the patients on Eli Lilly's weight loss drug Zepbound and diabetes Drug Mounjaro and the generic injection in Liraglutid could access his platform. But in contrast to the cooperation of the company with Novo Nordisk, Lilly published an explanation in which she clarified that it has “no belonging” to Hims & Husen.
HIMS & HINS began to prescribe an increased Semaglutide, the active ingredient in Novo Nordisks Diabetes Drug Ozempic and Wegven, in May 2024. The company had to stop mostly to measure the medication compiled, but some consumers can still be able to use personalized cans if this is clinically suitable and creative.
“That was one of the first things we shared with Novo is that we will always fight in the name of what consumers believe that we have the right to get the right,” said Dudum. “The regulation is very clear.”
During the lack of pharmacists concluded by the Food and Drug Administration, pharmacists can legally produce versions of branded medication. They can also be manufactured on a case -by -case basis if it is medically necessary for a patient, e.g.
However, drug manufacturers and some health experts are committed to practice, especially because the FDA does not agree to drugs.
Larger, state -regulated compounding pharmacies that make copies of Semaglutid in a loose fill without recipes are confronted with a legal period of May 22nd to stop marketing and selling these versions. Smaller, state-licensed compounding pharmacies that produce SEMAGLUTID subsequent attacks for individual recipes had a deadline of April 22.
“The spirit of it is that we remain true to the rules,” said Moore. “This is the best way for us to serve patients.”
– Brandon Gomez and Angelica Peebles from CNBC contributed to this report.
Comments are closed.